EcoDrugPlus

Trifunctional Purine Biosynthetic Protein Adenosine-3-Like

Ensembl ID : ENSGEVG00005003751
Gene Symbol: LOC115644292
2 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tryptophan Hydroxylase 1

Ensembl ID : ENSGEVG00005011260
Gene Symbol: TPH1
1 Cross references
258 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Alpha 4a

Ensembl ID : ENSGEVG00005010530
Gene Symbol: TUBA4A
3 Cross references
225 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Alpha-3 Chain

Ensembl ID : ENSGEVG00005010818
Gene Symbol: LOC115657344
2 Cross references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 1 Class Vi

Ensembl ID : ENSGEVG00005009359
Gene Symbol: TUBB1
1 Cross references
120 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 4b Class Ivb

Ensembl ID : ENSGEVG00005011522
Gene Symbol: TUBB4B
2 Cross references
74 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta-1 Chain-Like

Ensembl ID : ENSGEVG00005006301
Gene Symbol: LOC115646465
2 Cross references
267 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta-2 Chain

Ensembl ID : ENSGEVG00005000037
Gene Symbol: LOC115646466
2 Cross references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tumor Protein P53

Ensembl ID : ENSGEVG00005014298
Gene Symbol: TP53
1 Cross references
254 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosinase

Ensembl ID : ENSGEVG00005002619
Gene Symbol: TYR
3 Cross references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine Hydroxylase

Ensembl ID : ENSGEVG00005014592
Gene Symbol: TH
3 Cross references
188 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine Kinase 2

Ensembl ID : ENSGEVG00005011784
Gene Symbol: TYK2
3 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).